At CPHI Milan 2024, Abzena showcased its latest innovations in cell line development and ADC manufacturing, featuring the advanced AbZelectPRO platform and ThioBridge linker technology.

As clinical trials evolve, electronic Clinical Outcome Assessments (eCOA) remain central to data quality but often lag in adoption due to complex setup and deployment challenges. Tim Davis, vice ...

Starget Pharma, an Israeli startup developing AI-powered precision therapies for difficult-to-treat cancers, has secured a $5.1 million investment from MD Anderson Cancer Center’s Cancer Focus fund.

Palomar Health Foundation ignites youth interest in healthcare with Middle School Medical Discoveries program. The Palomar Health Foundation recently completed its third annual Middle School Medical ...

Scemblix is the first drug to show superiority over all standard of care therapies for a rare type of leukemia. Novartis’ Scemblix (asciminib) has received accelerated approval by the US FDA as a ...

Clinical trial results have revealed that semaglutide treatment significantly reduced hospital admissions in overweight and obese adults with heart disease. Novo Nordisk has released data from the ...

Advances in medicinal chemistry are driving the development of more sophisticated compounds, often with highly targeted mechanisms of action. These innovations, while promising, are also pushing the ...

A new case study released by AllazoHealth reveals that a leading rare disease pharmaceutical company achieved a 10.4% increase in therapy initiation, driven by AI-enabled patient outreach and ...

At CPHI Milan 2024, Abzena showcased its latest innovations in cell line development and ADC manufacturing, featuring the advanced AbZelectPRO platform and ThioBridge linker technology. By offering ...

Abbisko’s small molecule drug pimicotinib has smashed the primary goal of a phase 3 trial for the treatment of tenosynovial giant cell tumor (TGCT), taking the asset a step further to the market in ...

As active pharmaceutical ingredients (APIs) and medicines become more complex and the demand for efficiency rises, drug developers and manufacturers must adapt their strategies to keep pace with the ...